NasdaqGS - Delayed Quote USD

Ionis Pharmaceuticals, Inc. (IONS)

36.76

+1.47

+(4.17%)

At close: 4:00:01 PM EDT

36.05

-0.71

(-1.93%)

After hours: 4:56:37 PM EDT

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 4 days ago

ESPR

IONS
+4.17%
Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 5 days ago

RXRX

IONS
+4.17%
Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 10 days ago

IONS
+4.17%
Ionis reports success in olezarsen trial for high triglycerides

The drug is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

Clinical Trials Arena 18 days ago

IONS
+4.17%

GLDAF
Ionis reports positive data from study of olezarsen for hypertriglyceridemia

The trial enrolled 1,478 subjects aged 18 years and above and diagnosed with, or at risk for, ASCVD.

Clinical Trials Arena 20 days ago

IONS
+4.17%
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Late-stage data shows that treatment with an 80mg dose of IONS' Tryngolza achieved a 61% placebo-adjusted reduction in triglyceride levels in six months.

Zacks 20 days ago

IONS
+4.17%
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

CARLSBAD, Calif., May 19, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <500 mg/dL) with or at risk for atherosclerotic cardiovascular disease (ASCVD). Nearly all the participants were on current standard of care lipid-lowering medicines. The trial met its primary endpoint with a statistically significant placebo-adjusted 61% and 58% re

Business Wire 21 days ago

IONS
+4.17%
Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against Billionaire Glenn Russell Dubin’s other stock picks with huge upside potential. Glenn Russell Dubin is one of the industry’s most […]

Insider Monkey 29 days ago

IONS
+4.17%
Ionis to host 2025 virtual Annual Meeting of Stockholders

CARLSBAD, Calif., May 06, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025.

Business Wire last month

IONS
+4.17%
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts

Shareholders in Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) may be thrilled to learn that the analysts have just...

Simply Wall St. last month

IONS
+4.17%
Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Ionis Pharmaceuticals ( NASDAQ:IONS ) First Quarter 2025 Results Key Financial Results Revenue: US$132.0m (up 11% from...

Simply Wall St. last month

IONS
+4.17%
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says

Ionis Pharmaceuticals (IONS) reported strong Q1 financial results, driven by increased commercial an

PREMIUM
MT Newswires last month

IONS
+4.17%
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

Zacks last month

IONS
+4.17%

AZN
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Ionis Pharmaceuticals Inc (IONS) reports a 10% revenue increase and raises 2025 guidance, driven by successful product launches and strategic initiatives.

GuruFocus.com last month

IONS
+4.17%
Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks last month

IONS
+4.17%
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.43% and 9.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

IONS
+4.17%
Ionis Pharmaceuticals: Q1 Earnings Snapshot

The Carlsbad, California-based company said it had a loss of 93 cents per share. Losses, adjusted for stock option expense, were 75 cents per share. The results beat Wall Street expectations.

Associated Press Finance last month

IONS
+4.17%
Ionis reports first quarter 2025 financial results

CARLSBAD, Calif., April 30, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025.

Business Wire last month

IONS
+4.17%
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

CARLSBAD, Calif., April 29, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were interested in trying a new prophylactic therapy, with nearly two-thirds (65%) reporting they haven’t yet found the best treatment option for them. The Ionis-sponsored survey was conducted online by The Harris Poll among 150 adults living with HAE and 228 allergists/immunologists who see HAE patients

Business Wire last month

IONS
+4.17%
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

IONS
+4.17%

Performance Overview

Return	IONS	S&P 500 (^GSPC)
YTD	+5.15%	+2.11%
1-Year	-5.62%	+12.32%
3-Year	+5.24%	+49.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ionis Pharmaceuticals, Inc. (IONS)

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Ionis reports success in olezarsen trial for high triglycerides

Ionis reports positive data from study of olezarsen for hypertriglyceridemia

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

Ionis to host 2025 virtual Annual Meeting of Stockholders

Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts

Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals: Q1 Earnings Snapshot

Ionis reports first quarter 2025 financial results

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?

Performance Overview